Revolution Medicines, Inc. $RVMD Shares Acquired by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP increased its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 199.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 242,029 shares of the company’s stock after purchasing an additional 161,237 shares during the quarter. Revolution Medicines accounts for about 7.5% of Seven Fleet Capital Management LP’s holdings, making the stock its 3rd largest holding. Seven Fleet Capital Management LP owned 0.11% of Revolution Medicines worth $45,327,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of RVMD. Contravisory Investment Management Inc. acquired a new stake in Revolution Medicines in the 2nd quarter worth about $32,000. Global Retirement Partners LLC lifted its position in shares of Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after acquiring an additional 361 shares in the last quarter. Torren Management LLC purchased a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $33,000. Johnson Financial Group Inc. acquired a new stake in shares of Revolution Medicines in the second quarter worth approximately $37,000. Finally, Arax Advisory Partners acquired a new stake in shares of Revolution Medicines in the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Insider Buying and Selling

In other news, insider Stephen Michael Kelsey sold 4,175 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $651,801.00. Following the sale, the insider owned 291,876 shares of the company’s stock, valued at approximately $45,567,681.12. The trade was a 1.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 60,400 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the completion of the transaction, the chief operating officer owned 158,222 shares in the company, valued at $25,342,417.74. This represents a 27.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 212,497 shares of company stock worth $38,206,486 over the last ninety days. 7.60% of the stock is currently owned by insiders.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: The FDA approval expands Revolution Medicines beyond clinical development and opens a potentially significant revenue opportunity in a cancer with substantial unmet treatment needs. The drug’s accelerated review and favorable efficacy profile reinforce investor confidence in the company’s RAS/MAPK-focused platform. Reuters FDA approval article
• Positive Sentiment: Management priced RASONQUE at approximately $39,800 per month, establishing a high-value commercial product and giving investors an initial benchmark for potential sales. RASONQUE pricing article
• Positive Sentiment: TD Cowen upgraded RVMD to “strong buy,” while other analysts have maintained bullish ratings and price targets above recent trading levels. Institutional ownership and reported purchases by some funds also provide supportive sentiment.
• Neutral Sentiment: The stock’s reaction has been relatively restrained despite the approval, likely because investors had anticipated the decision and RVMD already trades at an elevated valuation after a substantial run-up.
• Negative Sentiment: The $39,800 monthly list price could intensify scrutiny from insurers, policymakers and patients, potentially limiting access or slowing adoption. This pricing concern may be offsetting some of the enthusiasm surrounding the FDA decision. Pricing impact article
• Negative Sentiment: Insider Mark Goldsmith sold 80,000 shares for about $16.7 million, reducing his holdings by roughly 23%. Although one insider transaction is not necessarily a change in fundamentals, it can create a modest sentiment overhang after the stock’s sharp appreciation. Insider sale article

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RVMD shares. HC Wainwright reaffirmed a “buy” rating and set a $195.00 target price on shares of Revolution Medicines in a research note on Monday, July 6th. Piper Sandler raised their price target on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wolfe Research restated an “outperform” rating and set a $220.00 price target on shares of Revolution Medicines in a research report on Monday, August 10th. Wedbush upped their price objective on shares of Revolution Medicines from $192.10 to $201.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Finally, Mizuho boosted their target price on Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $167.89.

Revolution Medicines Stock Up 1.9%

NASDAQ RVMD opened at $215.44 on Thursday. The business’s fifty day simple moving average is $191.27 and its 200-day simple moving average is $147.30. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The firm has a market cap of $46.18 billion, a PE ratio of -24.43 and a beta of 1.39. Revolution Medicines, Inc. has a 52 week low of $35.64 and a 52 week high of $220.34.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the firm earned ($1.31) EPS. As a group, equities analysts anticipate that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.